Immunooncology

In the field of immunotherapy (immuno-oncology, I/O), new-generation antibodies are being developed in formats that improve their pharmacological properties. These molecules are designed to interact with immune cells in the tumor microenvironment with the goal of activating them to kill tumor cells, or to negate the immune suppression caused by the tumor. For the discovery of molecular target binding sequences used in the design of next-generation antibodies, Pure Biologics uses a proprietary technology platform, PureSelect2, in addition to libraries licensed from Twist Bioscience, and its own ScFv antibody fragment sequence library, PureLibra.